Reactogenicity to COVID-19 vaccination in the United States of America

Purpose: In the United States, Pfizer-BioNTech, Moderna, and Janssen's coronavirus disease 2019 (COVID-19) vaccines have been granted Emergency Use Authorization (EUA) with the Pfizer-BioNTech vaccine presently approved by the US Food and Drug Administration. The purpose of this study is to ana...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental vaccine research (Seoul) 2022, Vol.11 (1), p.104-115
Main Authors: Adekunle Sanyaolu, Aleksandra Marinkovic, Stephanie Prakash, Priyank Desai, Nafees Haider, Abu Fahad Abbasi, Nasima Mehraban, Isha Jain, Amarachi Ekeh, Omar Shazley, Chuku Okorie, Verner N. Orish
Format: Article
Language:Korean
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: In the United States, Pfizer-BioNTech, Moderna, and Janssen's coronavirus disease 2019 (COVID-19) vaccines have been granted Emergency Use Authorization (EUA) with the Pfizer-BioNTech vaccine presently approved by the US Food and Drug Administration. The purpose of this study is to analyze passive surveillance data on COVID-19 vaccine adverse reaction in the United States. Materials and Methods: We analyzed passive surveillance data on COVID-19 vaccine adverse reactions which were retrieved from the Vaccine Adverse Event Reporting System database. Retrieved records on demographic information as well as the top 10 common vaccine adverse events were extracted and assessed from 200 of the most recently reported cases for the study analysis. Results: Local and systemic adverse reactions were reported in the study. A significant difference (p
ISSN:2287-3651
2287-366X